Australia has the opportunity to be a global leader in safe, balanced, and evidence-based regulation of medicinal cannabis. This requires moving beyond outdated prejudices, recognising the unique properties of natural therapeutics, and respecting the central role of the doctor–patient relationship. Over-regulation and prohibitionist tendencies will only drive use underground, increasing risks and reducing oversight.

Regulating emerging therapies should not proceed without a proportional analysis of the effect on patient outcomes and risks.

My experience with AHPRA Investigators and the Board - the motivation behind much of my advocacy and educational work.

Is AHPRA spending money it doesn’t have doing things that are unlikely to affect patient outcomes?